儿童IDH突变型胶质瘤的频率、基因组景观和结局的多机构研究
该多机构研究对851例接受下一代测序的儿童胶质瘤患者进行分析,发现78例存在IDH1/2突变,0-9岁组频率为0.5%(2/378),10-21岁组为16.1%(76/473)。低级别胶质瘤中84%的患者接受观察性管理而未接受辅助治疗,低级别星形细胞瘤5年无进展生存率为42.9%(95%CI:20.3-63.8),尽管短期总生存期良好,但10年后有多例疾病相关死亡报告。
要点
- 儿童胶质瘤中IDH1/2突变在10-21岁组频率为16.1%(76/473),远高于0-9岁组的0.5%(2/378)。
- 低级别胶质瘤中84%的患者接受初始观察性管理而未接受辅助治疗。
- 低级别星形细胞瘤5年无进展生存率为42.9%(95%CI:20.3-63.8),10年后有多例疾病相关死亡报告。
核心结论
- 一部分儿童胶质瘤由IDH1/2突变驱动,青少年中发生率更高。
- 大多数患者接受初始观察性管理而未接受辅助治疗。
- 研究结果提示儿童IDH1/2突变型胶质瘤的自然病史可能与成人相似,但需要额外研究。
研究设计与样本
- 多机构分析,通过下一代测序(NGS)识别儿童IDH1/2突变型胶质瘤的频率。
- 同时回顾性审查儿童IDH1/2突变型胶质瘤,分析临床基因组特征、治疗方法和结局。
主要发现
- 在851例接受NGS的儿童胶质瘤患者中,识别出78例携带IDH1/2突变。
- 0-9岁和10-21岁患者中,分别有2/378(0.5%)和76/473(16.1%)携带IDH1/2突变肿瘤。
- IDH突变频率在低级别胶质瘤(52/570,9.1%)和高级别胶质瘤(25/277,9.0%)之间相似。
- 4例肿瘤组织学分级为中间级别,其中1例携带IDH1突变。
- 76例IDH1/2突变型胶质瘤患者有结局数据;低级别胶质瘤中84%的患者接受观察性管理而未接受额外治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要额外研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence and biology of IDH1/2 mutations in pediatric gliomas are unclear. Notably, current treatment approaches by pediatric and adult providers vary significantly. We describe the frequency and clinical outcomes of IDH1/2-mutant gliomas in pediatrics. METHODS: We performed a multi-institutional analysis of the frequency of pediatric IDH1/2-mutant gliomas, identified by next-generation sequencing (NGS). In parallel, we retrospectively reviewed pediatric IDH1/2-mutant gliomas, analyzing clinico-genomic features, treatment approaches, and outcomes. RESULTS: Incidence: Among 851 patients with pediatric glioma who underwent NGS, we identified 78 with IDH1/2 mutations. Among patients 0-9 and 10-21 years old, 2/378 (0.5%) and 76/473 (16.1%) had IDH1/2-mutant tumors, respectively. Frequency of IDH mutations was similar between low-grade glioma (52/570, 9.1%) and high-grade glioma (25/277, 9.0%). Four tumors were graded as intermediate histologically, with one IDH1 mutation. Outcome: Seventy-six patients with IDH1/2-mutant glioma had outcome data available. Eighty-four percent of patients with low-grade glioma (LGG) were managed observantly without additional therapy. For low-grade astrocytoma, 5-year progression-free survival (PFS) was 42.9% (95%CI:20.3-63.8) and, despite excellent short-term overall survival (OS), numerous disease-related deaths after year 10 were reported. Patients with high-grade astrocytoma had a 5-year PFS/OS of 36.8% (95%CI:8.8-66.4) and 84% (95%CI:50.1-95.6), respectively. Patients with oligodendroglioma had excellent OS. CONCLUSIONS: A subset of pediatric gliomas is driven by IDH1/2 mutations, with a higher rate among adolescents. The majority of patients underwent upfront observant management without adjuvant therapy. Findings suggest that the natural history of pediatric IDH1/2-mutant glioma may be similar to that of adults, though additional studies are needed.
引用
- Yeo KK, Alexandrescu S, Cotter JA, et al. Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. Neuro Oncol. 2023. PMID: 35604410. doi:10.1093/neuonc/noac132
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。